These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34694872)

  • 1. Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.
    Kim J; Choi J; Kang H; Ahn J; Hutchings J; van Niekerk C; Park D; Kim J; Jeon Y; Nam K; Shin S; Shin BS
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0143621. PubMed ID: 34694872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.
    Kim J; Choi J; Kang H; Ahn J; Hutchings J; Niekerk CV; Kim J; Jeon Y; Nam K; Kim TH; Shin BS; Shin S
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0112322. PubMed ID: 36507677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of mycobacterial CIII
    Yanofsky DJ; Di Trani JM; Król S; Abdelaziz R; Bueler SA; Imming P; Brzezinski P; Rubinstein JL
    Elife; 2021 Sep; 10():. PubMed ID: 34590581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.
    Komm O; Almeida DV; Converse PJ; Omansen TF; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0141821. PubMed ID: 34460302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
    Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of LBPT and its primary metabolites, as well as tolerability in the first-in-human study.
    Wang H; Liu H; Liu M; Wang W; Zhu L; Huang H; Hu P; Jiang J
    Eur J Pharm Sci; 2017 Mar; 100():87-93. PubMed ID: 28057550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telacebec (Q203), a New Antituberculosis Agent.
    de Jager VR; Dawson R; van Niekerk C; Hutchings J; Kim J; Vanker N; van der Merwe L; Choi J; Nam K; Diacon AH
    N Engl J Med; 2020 Mar; 382(13):1280-1281. PubMed ID: 32212527
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
    Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
    J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.
    Almeida DV; Converse PJ; Omansen TF; Tyagi S; Tasneen R; Kim J; Nuermberger EL
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
    Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
    Ceska Slov Farm; 2021; 70(5):164–171. PubMed ID: 34875838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
    Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
    Ceska Slov Farm; 2021; 70(5):164-171. PubMed ID: 35114793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study.
    Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB).
    Lee BS; Pethe K
    Expert Opin Investig Drugs; 2022 Feb; 31(2):139-144. PubMed ID: 35034512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects.
    Nelson CH; Etchevers K; Yi S; Breckenridge D; Hepner M; Patel U; Ling J; Mathias A
    Clin Pharmacokinet; 2020 Sep; 59(9):1109-1117. PubMed ID: 32333325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects.
    Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel H
    Br J Clin Pharmacol; 2021 Nov; 87(11):4354-4365. PubMed ID: 33837574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT
    Nirogi R; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2021 May; 41(5):469-482. PubMed ID: 33788154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
    Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
    Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.